A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer

Trial Profile

A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Dasatinib (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms READY
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 May 2014 as per ClinicalTrials.gov record.
    • 18 Jan 2014 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top